Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maeghan Chapman

Physician Assistant, Medical West Hartford, CT Physician Assistant

NPI 1063064665 CMS profile 10453703

65 Memorial Rd Ste 508, West Hartford, CT 06107

Open in the dashboard

General payments

$6,411

251 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maeghan Chapman of West Hartford, CT is reported in the CMS Open Payments database as having received $6,411 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $221 12
2024 General $1,132 60
2023 General $735 51
2022 General $2,863 59
2021 General $1,460 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maeghan Chapman
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Maeghan Chapman were reported at $221. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Maeghan Chapman Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,460 $156 $41–$563 $132
2022 $2,863 $185 $55–$649 $149
2023 $735 $199 $58–$717 $160
2024 $1,132 $206 $62–$740 $164
2025 $221 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,432 157 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $2,079 19 payments
  3. Biohaven Pharmaceuticals, Inc. $436 15 payments
  4. Teva Pharmaceuticals USA, Inc. $429 15 payments
  5. Amgen Inc. $311 7 payments
  6. Pfizer Inc. $172 9 payments
  7. Lundbeck LLC $167 8 payments
  8. Lilly USA, LLC $133 7 payments
  9. Allergan Inc. $127 7 payments
  10. Upsher-Smith Laboratories LLC $64 4 payments
  11. Other $60 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,637 249 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,440 1 payment
  3. Travel and Lodging $334 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $2,516 34 payments
  2. UBRELVY $1,713 111 payments
  3. QULIPTA $1,267 81 payments
  4. AJOVY $429 15 payments
  5. AIMOVIG $311 7 payments
  6. NURTEC ODT Pain $157 8 payments
  7. ZAVZPRET $146 8 payments
  8. BOTOX Hyperhydrosis $140 8 payments
  9. VYEPTI $131 6 payments
  10. BOTOX Botox Therapeutic $124 7 payments
  11. Other $375 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

546

Median for Physician Assistant: 241

Drug cost

$290,681

Median for Physician Assistant: $4,110

Branded share of claims

61.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 65 $89,386
Qulipta Atogepant Brand 42 $52,506
Emgality Pen Galcanezumab-Gnlm Brand 72 $50,405
Nurtec Odt Rimegepant Sulfate Brand 31 $34,274
Ajovy Autoinjector Fremanezumab-Vfrm Brand 39 $28,236
Botox Onabotulinumtoxina Brand 11 $14,650
Aimovig Autoinjector Erenumab-Aooe Brand 19 $14,222
Sumatriptan Succinate Generic 64 $3,690
Naratriptan Hcl Generic 21 $755
Candesartan Cilexetil Generic 12 $656

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$49,043

Of which drugs: $38,643

Medicare patients

37

Average age 64

Services billed

7,932

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 54%
Depression 46%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 7,802 $38,643

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $335
$335 42 —
UBRELVY
  • AbbVie, Inc. $301
$301 65 —
AJOVY
  • Teva Pharmaceuticals USA, Inc. $223
$223 39 —
VYEPTI
  • Lundbeck LLC $88
$88 — —
NURTEC ODT
  • PFIZER INC. $67
$67 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record